GUIDED THERAPEUTICS INC
GTHPdata completeness 88%16 fiscal years on filei. The business — what you’d actually own
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $81,0001 | $13,0002 | $98,0003 | $7,0004 | $767,0004 |
| Net income | −$2.07M5 | −$4.34M6 | −$3.49M7 | −$2.42M8 | −$3.2M8 |
| Operating cash flow | −$1.59M9 | −$1.48M10 | −$1.75M11 | −$1.12M12 | −$1.07M12 |
| Capital expenditure | $14,00013 | $31,00014 | $014 | $015 | $2,00015 |
| Free cash flow (derived) | −$1.61M9 | −$1.51M10 | −$1.75M11 | −$1.12M12 | −$1.07M12 |
| Total debt | $930,00016 | $17,00016 | $017 | — | — |
| Cash & equivalents | $643,00018 | $2.31M18 | $591,00019 | $388,00019 | $63,00019 |
| Diluted shares | 13.4M | 32.5M | 51.1M | 57.3M | 78.4M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.77
your share of equity
Profit it earned you last year
−$0.41
Free cash flow it threw off
−$0.14
Debt you’d be carrying
—
10 shares is a claim on −$0.77 of net worth that earned you −$0.41 and generated −$0.14 of cash last year.
iii. Is this a good business?
Moat signal · return on equity
— avg · 5y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
+486% shares · 5y
Share count is up 486% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has fallen 100% — deleveraging.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 10-K · period ending 2021-12-31 · accession 0001477932-23-001899 (Revenues)
- 10-K · period ending 2022-12-31 · accession 0001477932-24-001549 (Revenues)
- 10-K · period ending 2023-12-31 · accession 0001477932-25-002200 (Revenues)
- 10-K · period ending 2024-12-31 · accession 0001477932-26-001723 (Revenues)
- 10-K · period ending 2021-12-31 · accession 0001477932-23-001899 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001477932-24-001549 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001477932-25-002200 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001477932-26-001723 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001477932-23-001899 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001477932-24-001549 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001477932-25-002200 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001477932-26-001723 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001477932-23-001899 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001477932-24-001549 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-12-31 · accession 0001477932-26-001723 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001477932-23-001899 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0001477932-24-001549 (LongTermDebtCurrent)
- 10-K · period ending 2021-12-31 · accession 0001477932-23-001899 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001477932-26-001723 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)